An Exploratory Evaluation of Interleukin 28B (IL28B) Genotype, Single Nucleotide Polymorphisms (SNP) of rs12356193, Protein and RNA Biomarkers in Serum Samples (Stored, Already Obtained From Completed Studies) From Subjects With HBe-antigen Positive or Negative Chronic Hepatitis B, Who Have Completed Therapy for Hepatitis B With Pegasys +/- Lamivudine.

Trial Profile

An Exploratory Evaluation of Interleukin 28B (IL28B) Genotype, Single Nucleotide Polymorphisms (SNP) of rs12356193, Protein and RNA Biomarkers in Serum Samples (Stored, Already Obtained From Completed Studies) From Subjects With HBe-antigen Positive or Negative Chronic Hepatitis B, Who Have Completed Therapy for Hepatitis B With Pegasys +/- Lamivudine.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2014

At a glance

  • Drugs Lamivudine (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Sponsors Roche
  • Most Recent Events

    • 25 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 08 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top